It is a fibrinolytic, which converts plasminogen into plasmin in order to inhibit blood clotting. It is used predominantly for the treatment of pulmonary embolisms, acute heart attacks and ischemic strokes.

Molecular size: Large

Controlled Substance: No

Precursor: No

Indications: Antithrombotic agents, Ophthalmological drugs

Status: Commercial

Axano Pharmaceuticals Ltd
contact us now